Close Menu

NEW YORK (GenomeWeb) – Drug discovery firm Immuneering is teaming with the UK-based Dementia Discovery Fund in an effort to identify new drug targets and candidates for patients with Alzheimer's disease.

The Dementia Discovery Fund, or DDF, said today that it will spend $1.3 million to use Immuneering's drug discovery platform to analyze public data sets on Alzheimer's patients. DDF and Immuneering hope to generate new molecular entities for potential treatment of the neurodegenerative disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.